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We previously cloned human G protein gamma 7 (GNG7) and demonstrated that it was downregulated in gastrointestinal cancer. The
significance of GNG7 expression in oesophageal cancer is unknown. TaqMan quantitative real-time PCR was performed to determine
the clinical significance of GNG7 expression in 55 cases of oesophageal cancer. Furthermore, GNG7-transfected oesophageal cancer
cells were analysed in laboratory studies at genomic and epigenetic levels. Twenty-seven patients with low GNG7 expression showed
significantly poorer survival than did 28 patients with high expression (Po0.05). Tumours with low GNG7 expression invaded deeper
than those with high GNG7 expression (Po0.05), both in vivo and in vitro. Eight tumours retained GNG7 expression, and they did not
show either promoter hypermethylation or loss of heterozygosity (LOH). In 38 tumours with GNG7 suppression, 22 (57%) showed
either LOH or promoter hypermethylation. In addition, GNG7 expression was significantly associated with the presence of miR328 in
oesophageal cancer cell lines, which suggests that this microRNA might be a regulator of GNG7 expression. GNG7 suppression
represents a new prognostic indicator in cases of oesophageal cancer. GNG7 might be suppressed by LOH and promoter
hypermethylation or by microRNA.
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Cell signalling mediated by small guanine nucleotide-binding
proteins (G proteins) such as ras (Bos, 1989), rho (Symons, 1995;
Boivin et al, 1996), and rac (Boivin et al, 1996) has been reported
in various cancers. In contrast, oncogenic changes mediated by
heterotrimeric large G proteins have been unknown and most
analyses of large G proteins have focused on solid carcinomas. In
our previous studies, we reported that large G protein gamma 7
(GNG7) was downregulated in pancreatic cancer patients (Shibata
et al, 1998) in 70% of gastrointestinal cancers and in 94% of
intrahepatic cholangiocarcinomas (Utsunomiya et al, 2002).
Among diverse solid carcinomas, we are presently focusing on
the relationship between loss of GNG7 expression and its clinical
significance in oesophageal carcinomas. Oesophageal cancer is
epithelial in origin with a high malignant potential and most
patients die from it (Holscher et al, 1995). Thus, we sought to
identify a marker for oncogenesis and progression of oesophageal
cancer. In the current study, we examined the clinical significance
of diminished GNG7 expression in oesophageal cancer cases and
determined whether its expression was altered at the genomic
level, mRNA level, epigenetic level or the microRNA level.
In general, tumour suppressor gene function may be lost at
genomic levels due to mutation, homozygous deletion, loss of
heterozygosity (LOH) and/or epigenetic changes such as DNA
methylation or histone deacetylation (Garinis et al, 2002). In
addition, recent studies disclosed that expression of several genes
was regulated by microRNA expression. With regard to expression
of microRNA, likely molecules that could be regulated can be
predicted based on information provided by a recently developed
website (http://microrna.sanger.ac.uk/targets/v3/). In this study,
two such microRNA molecules were examined for their regulation
of GNG7 expression in cultured cell lines.
In preliminary studies, we evaluated the expression of GNG7 in
10 oesophageal cancer patients (Shibata et al, 1999). In the current
study, we significantly expanded that work with additional cases
and analysed clinicopathologic information to determine the
precise role of GNG7 in oesophageal cancer.
MATERIALS AND METHODS
Cell lines and tissues
Fifteen human oesophageal carcinoma cell lines were prepared.
The TE series was provided by the Cell Resource Center for
Biomedical Research Institute of Development, Aging and Cancer,
Tohoku University, Japan. The KYSE series was a generous gift
from Dr Shimada (Kyoto University, Kyoto, Japan). GNG7
transfectants with pcDNA3-GNG7 (GNG7 expression vector) and
mock cell lines were established in KYSE150 according to methods
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sdescribed previously (Shibata et al, 1999). After 24h, the cells were
subcultured and selected in G418-containing medium. After 2
weeks, colonies were transferred separately to individual wells and
established as transfectants. Real-time PCR (RT-PCR) and
immunoblotting confirmed GNG7 expression in the transfectants.
Primary tumour tissue specimens and corresponding normal
tissue controls were obtained from 55 Japanese patients who
underwent surgery for oesophageal carcinoma (47 men and 8
women; median age, 61 years; range, 40–82 years). Written
informed consent was obtained from these patients. Histologically,
47 tumours were classified as squamous cell carcinoma, two as
adenocarcinoma and six as other types. Follow-up ranged from 3
to 4159 days.
DNA and RNA extraction
Tissue samples were excised and immediately stored at  801C.
DNA and RNA were extracted according to methods described
previously. Tumour tissues containing more than 80% tumour
cells had shown H&E staining.
TaqMan quantitative RT-PCR analysis
TaqMan RT-PCR for GNG7 and 18s cDNA was performed using an
ABI PRISM 7000 (Applied Biosystems, Tokyo, Japan; Chen, 2005),
according to the manufacturer’s instructions and our previous
study (Shibata et al, 1999). The expression levels were normalised
to 18s rRNA. The cases were then classified into two groups
according to the median expression value (0.32), that is, a GNG7
high-expression group (tumour/normal (T/N)40.32; n¼27) and a
GNG7 low-expression group (T/No0.32: n¼28).
Invasion assay
The invasion assay was performed in 24-well trays using inserts
with 8mm pore size (Becton Dickinson, Franklin Lakes, NJ, USA)
as described previously. For invasion assays, inserts were coated
with Matrigel (100mgcm
 2) (Becton Dickinson). Oesophageal
cancer cells were suspended in RPMI-1640 medium at
5 10
4ml
 1 and added to inserts, which were transferred to wells
containing RPMI-1640 medium with 10% FBS. After incubation for
6 or 24h, cells on the lower surface of the membrane were stained
for light microscopy. Five different fields were assessed ( 200).
Assays were performed in triplicate.
LOH analysis
In the following studies, we utilised 42 of 55 cases, all with
informed consent. We defined abnormal GNG7 mRNA expression
in the tumour tissue as an expression that was less than 20% of
that seen in normal tissue specimens. Paired normal and tumour
DNA samples were analysed with two polymorphic microsatellite
markers. Allelic deletions of chromosome 19p region flanking the
GNG7 gene were assessed using markers D19S1166 and D19S565.
The former region is  0.6Mb from the GNG7 gene, while the latter
is an intragene marker. All of the microsatellite markers used in
this analysis were CA-repeat markers. The primer sequences were
obtained from the Genome Database (D19S1166: forward:
TTCCAGCCTAGGTAGCAGTG, reverse: GCAACTGAGGAAATGC
ATCTD; 19S565: forward: GTGATTGCACCACGGG, reverse: TCAA
GTCATTGGGTTGGC). PCR was performed in 10ml reaction
volumes containing 0.1mM each of FAM-labelled forward and
unlabelled reverse primers, 0.19mM dNTP mix, 1  PCR buffer,
0.4U AmpliTaq Gold polymerase (Applied Biosystems) and 100ng
of genomic DNA. Amplification was performed in an iCycler (Bio-
Rad, Hercules, CA, USA) with an initial cycle of 951C for 5min,
followed by 30 cycles of 951C for 50s, 551C for 60s and 721C for
60s, with a final extension at 721C for 10min. After 1ml of each
PCR product was diluted with 7ml of DNase-free, RNase-free
distilled water, 0.1ml of each diluted sample was added to 0.7mlo f
formamide and 0.3ml of ROX 400HD size standard and denatured
at 951C for 5min before loading the samples into the Applied
Biosystems 373 DNA sequencer (Applied Biosystems). Analysis of
raw data and assessment of LOH were performed with GeneScan
Analysis v.2.0.0 software (Applied Biosystems). Cases met LOH
criteria when an allele peak signal from tumour DNA was reduced
by 50% compared with the normal counterpart.
Bisulphite treatment
We extracted genomic DNA and carried out bisulphite modifica-
tion of genomic DNA as described previously (Yamashita et al,
2002). Briefly, 2mg of DNA in 20mlo fH 2O containing 5mgo f
salmon sperm DNA were denatured by incubation with 0.3 M
NaOH at 501C for 20min. The DNA was then incubated at 701C for
3h in a 500-ml reaction mixture containing 2.5 M sodium
metabisulphite and 0.125 M hydroquinone (pH 5.0). The treated
DNA was purified with the Wizard DNA purification system
according to the manufacturer’s instructions (Promega, Madison,
WI, USA) and finally resuspended in 100mlo fH 2O after ethanol
precipitation.
5-AZAC treatment of oesophageal cancer cell lines
To evaluate the methylation status of the promoter region of GNG7
in oesophageal cancer, cell lines were treated with a demethylating
drug, 5-AZAC, as in our previous study (Mori et al, 1996). We
analysed GNG7 expression by quantitative RT-PCR before and
after 5-AZAC treatment in 15 oesophageal cancer cell lines.
Methylation analysis
The assay involved sodium bisulphite modification followed by
sequence and pyrosequencing to determine the methylation status
of GNG7 promoter region. DNA methylation patterns in the
promoter region of the GNG7 gene were (Bottoni et al, 2005)
determined by sequencing bisulphite-treated DNA. We used three
paired primers for the analysis. The primers were as follows: F1, 50-
TAATCTTTCCTAACTCCCACTAAAA-30; R1, 50-AGTAGTAGAGT
AGTGGTGGTTTAAT-30; F2, 50-CCAAAACCAAAAAATCAATA-30;
R2, 50-TTTTAGTGGGAGTTAGGAAAGATTA-30; F3, 50-CCAACCC
CACAATCAAAATCCAATC-30; and R3, 50-TTTTTATTGATTTTTT
GGTTTTGGG-30. PCR was performed in 25-ml reaction volumes
containing 16.6mM ammonium sulphate, 67mM (pH 8.8) Trizma,
6.7mM MgCl2,1 0 m M 2-mercaptoethanol, 10mM DMSO, 1.25mM
dNTP, 1.6mM of each primer, 2.5U of platinum Taq (Perkin-Elmer,
Foster City, CA, USA), and 50ng of bisulphite-treated DNA. PCR
cycling conditions (Touchdown PCR) were as follows: 5min at
951C, two cycles of 60s denaturation at 941C, 60s at 661C
annealing temperature, a 120s extension at 721C, two cycles of 60s
at 941C, 60s at 64, 62, 60, 58, and 561C, 120s at 721C, 30 cycles of
60s at 941C, 60s at 541C, 120s at 721C, and a final extension step of
7min at 721C. To verify the methylation status, DNA bands of each
transcript were excised from the gel, purified using the QIAquick
gel extraction kit (Qiagen, Valencia, CA, USA) and sequenced on
the Applied Biosystems Prism 377 DNA sequencing system.
Pyrosequencing-based typing
We chose a region located in CpG islands of GNG7 for PSQ
analysis to detect methylation status. PCR primers were designed
to be fully complementary to the deaminated strand (forward: 50-
GAAAGTGGAAATTGGGGATAAAT-30, reverse: 50-biotin label-
CCTCCAAACCTTAATAAAAATCAAA-30). For this region, PCR
was performed in 30ml reaction volumes containing 16.6mM
ammonium sulphate, 67mM (pH 8.8) Trizma, 6.7mM MgCl2,
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s10mM 2-mercaptoethanol, 10mM DMSO, 1.25mM dNTP, 1.6mM of
each forward and reverse (biotinylated) primer, 25ng of bisul-
phite-converted DNA as template, and 2.5U of platinum Taq
(Perkin-Elmer). The PCR programme consisted of a denaturing
step of 4min at 951C followed by 50 cycles of 30s at 951C, 30s at
601C, 60s at 721C, with a final extension for 5min at 721C. The
amplification cycle was repeated 50 times to ensure complete
consumption of the biotinylated primers to avoid background
signals during pyrosequencing. Within the PCR region, we
designed three sequencing primers (50-AAGTGGAAATTGGGGA
TAAA-30,5 0-GGTTAATAGGAAGGAAAGAA-30,5 0-GGTTAGGTT
TYGTATT-30) to cover four CpG arrangements. A PCR product
(25ml) was used for each sequencing reaction. Purification with
streptavidin sepharose beads and codenaturation of the biotiny-
lated PCR products and the sequencing primer (15pmol per
reaction) were conducted following the PSQ sample preparation
guide using a filter plate device. After completion of primer
annealing, 500ng of SSB was added to the sequencing reaction mix.
Sequencing was performed on the PSQ 96 MA system with SQA
reagent kit according to the manufacturer’s instructions. Pyrose-
quence data were quantified and background corrected using PSQ
96 MA version 2.0.2 software (Pyrosequencing AB, Stockholm,
Sweden). Tumour tissues were defined as methylation-positive
when a methylation allele peak signal from tumour DNA was 10%
elevated compared with the normal counterpart.
Regulation of GNG7 expression and the presence of
microRNA
Total RNA was extracted from 16 oesophageal cancer cell lines:
TE6, TE8, TE10, TE12, TE14, TE15, KYSE110, KYSE140, KYSE180,
KYSE220, KYSE270, KYSE450, KYSE500, KYSE700, KSE1 and
KSE2. When the cell density reached 75% confluency, RNA was
extracted using the Trizol
s total RNA isolation reagent (Gibco
BRL, Life Technologies, Gaithersburg, MD, USA) as per the
manufacturer’s protocol. Total RNA was isolated from frozen
tissues after disruption with an Ultra Turrax T25 homogeniser
using Trizol. RNA concentrations were quantified using a
NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington,
Delaware, USA). cDNA was synthesised from total RNA using
gene-specific primers according to the TaqMan MicroRNA Assays
protocol (PE Applied Biosystems, Foster City, CA, USA). Reverse
transcriptase reactions contained 10ng of RNA, 50nM stem-loop
RT primer, 1  RT buffer, 0.25mM each of dNTPs, 3.33Uml
 1
MultiScribe reverse transcriptase and 0.25Uml
 1 RNase Inhibitor
(all purchased from cDNA Archive kit of Applied Biosystems). The
7.5ml reactions were incubated in a Bio-Rad i-Cycler in a 96-well
plate for 30min at 161C, 30min at 421C, 5min at 851C, and then
held at 41C. Real-time PCR for microRNA was performed using an
Applied Biosystems 7500 Real-Time PCR System. The 10ml PCR
included 0.67ml RT products, 1  TaqMan Universal PCR master
mix and 1ml primers and probe mix according to the TaqMan
MicroRNA Assays protocol (PE Applied Biosystems). The reac-
tions were incubated in 96-well optical plates at 951C for 10min,
followed by 40 cycles of 951C for 15s and 601C for 10min. Those
data were determined using the default as the fractional cycle
number at which fluorescence passed the fixed threshold.
According to the website (http://microrna.sanger.ac.uk/targets/v3/),
two kinds of microRNA, miR15a (Hoglund et al, 1998) and
miR328, were chosen as candidates to regulate GNG7 expression.
On the basis of the PCR for miR15a and miR328, the amplified
products were present in 10 and 16 out of 16 cell lines, respectively.
Statistical analysis
Fisher’s exact test and Student’s t-test were used for statistical
analysis; P-values o0.05 were regarded as statistically significant.
RESULTS
Expression of GNG7 mRNA in oesophageal tumours,
normal tissues and cell lines
As shown in Figure 1, tumour samples (relative expression: 0.096)
expressed GNG7 at significantly lower levels than did normal
samples (relative expression: 0.23) (Po0.0001). Interestingly, in 45
of 55 oesophageal cancer tissue specimens (82% of total), the level
of GNG7 suppression was at least 80% compared to the level of
corresponding normal tissue specimens. In oesophageal tumour
cell lines, the average expression level of GNG7 was quite low
(relative expression: 0.11), similar to results obtained with clinical
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Figure 1 Expression of GNG7 mRNA and patient survival. (A)
Expression of GNG7 mRNA in tumour samples, normal tissues and cell
lines. GNG7 mRNA expression was determined in oesophageal cancer
tissues and corresponding normal tissues obtained from 55 Japanese
patients who underwent surgery for oesophageal carcinoma. Figure also
shows GNG7 expression in 15 cell lines established from oesophageal
cancer tissue. Expression ratios were calculated by dividing the amplified
GNG7 expression level by the expression of 18s ribosomal RNA. Tumour
samples (relative expression: 0.096) expressed GNG7 at significantly lower
levels than did normal samples (relative expression: 0.23) (Po0.0001). (B)
Electrophoresed amplified products of GNG7 and GAPDH in tumour and
the corresponding normal tissue from four representative oesophageal
cancer cases. (C) Survival curves of 55 cases of oesophageal cancer in
relation to GNG7 expression. Oesophageal cancer patients were divided
into two groups relative to the median expression value (0.32), yielding a
GNG7 high-expression group (T/N40.32; n¼27) and a GNG7 low-
expression group (T/No0.32; n¼28).
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stumour samples. It is worth describing that the GNG7 expression
in cancer cell lines was low in comparison with samples from
cancer tissues. In contrast to the cancer tissues that contained
normal stromal cells, the 15 cancer cell lines were not contami-
nated with normal cells. Therefore, we speculated that clinical
samples with stromal cells showed much higher GNG7 expression
than the cancer cell lines. Furthermore, we divided 55 oesophageal
cancer cases into two groups based on the median relative
expression value for GNG7 (T/N¼0.32). Thus, 27 cases were above
the median and considered in the high GNG7 expression group,
while 28 were placed in the low GNG7 expression group.
Correlation of clinicopathologic factors and the expression
of GNG7 in oesophageal cancer
Clinicopathologic analysis of the high- and low-expression groups
showed that low GNG7 expression was significantly associated with
greater depth of tumour invasion (Table 1, Po0.05). The survival
curve of 55 patients in relation to GNG7 expression status is shown
in Figure 1C. The patients with low GNG7 expression showed a
significantly poorer survival than did those with high expression
(Po0.05). In contrast, no significant differences were observed in
GNG7 gene expression status when patients were categorised by
age, gender, histological type, lymph node metastasis, lymph vessel
permeation and venous permeation. Considering clinical applica-
tion, even though 12 cases with tumour were restricted within the
oesophageal wall, 9 cases (75%) were classified into the poor
prognosis group. Although multivariate analysis did not disclose
the statistical significance of GNG7 in predicting prognosis, several
cases of tumour restricted in the oesophageal wall and with lower
expression of GNG7 were useful in predicting poorer prognosis
than the depth of tumour invasion.
Invasion assay
Since the expression of GNG7 was associated with the depth of
tumour invasion, the transwell invasion assay was performed to
determine whether invasive activity was directly mediated by
expression of GNG7 in oesophageal cancer cell lines. We compared
GNG7 transfectants with the parental cell line KYSE150 and a mock
cell line. High expressers of GNG7 (transfectant A, average
intensity¼2.08 and transfectant B, average intensity¼1.87) were
significantly less invasive than KYSE150 (average intensity¼2.55)
and the mock cell line (average intensity¼2.82) (Figure 2A,
Po0.05). These in vitro results were concordant with clinico-
pathologic data and support the hypothesis that GNG7 modulates
tumour cell invasiveness.
LOH analysis at 19p13.3
We first examined the LOH in the GNG7 region (Figure 3A). Loss
of heterozygosity in the GNG7 region at 19p13.3 was examined in
Table 1 Relationship between clinicopathologic variables and GNG7
expression in oesophageal cancer patients
GNG7 expression
High Low P-value
Age (years) 0.209
o62 14 18
462 14 9
Sex 0.476
Male 23 24
Female 5 3
Histology
a 0.576
Well 6 7
Mod 14 9
Poor 4 7
Other 4 4
Depth
b o0.05
Within 3 9
Beyond 25 18
Lymph node metastasis 0.10
Negative 8 3
Positive 20 24
Lymph vessel permeation 0.451
Negative 11 8
Positive 17 19
Venous permeation 0.134
Negative 16 10
Positive 12 17
GNG7¼G protein gamma 7.
aWell¼well-differentiated squamous cell carcinoma;
mod¼moderately differentiated squamous cell carcinoma; poor¼poorly differ-
entiated squamous cell carcinoma; other four cases are mucinous adenocarcinoma.
bWithin and beyond the oesophageal wall.
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Figure 2 Biologic characteristics of GNG7-transfected oesophageal
cancer cells. (A) Invasion assay for GNG7 transfectants. After incubation
for 6 or 24h, the number of cells on the lower surface of the membrane
was counted in five different fields ( 200). Clone A and clone B GNG7
transfectants were compared with the parental cell line KY150 and the
mock cell line. GNG7 transfectants A (average intensity¼2.08) and B
(average intensity¼1.87) were significantly less invasive than parental cells
(average intensity¼2.55) and mock cells (average intensity¼2.82)
(Figure 3, Po0.05). (B) Reactivation of GNG7 expression by 5-AZAC
treatment. Analysis of four representative oesophageal cancer cell lines.
Data indicate that GNG7 expression may be regulated by methylation. (C)
Increased expression of GNG7 after 5-AZAC treatment in 15 oesophageal
cancer cell lines. The vertical axis indicates the calculated ratio of GNG7
expression with and without 5-AZAC treatment.
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s42 oesophageal cancer cases using two microsatellite markers. The
frequencies of LOH for each microsatellite marker in informative
cases were 9 out of 32 (28%) and 3 out of 29 (10%) for D19S1166
and D19S565, respectively. Loss of heterozygosity was detected in
10 out of 40 (25%) tumours that were informative for at least one
of the two markers at the 19p13.3 region. We also examined the
relationship between LOH and the suppression ratio of GNG7
mRNA (Table 2). All 10 LOH-positive cases (100%) had
suppressed expression of GNG7 (T/No0.8). There was a
significant correlation between the presence of LOH and the
suppression ratio of GNG7 mRNA (Po0.01).
Reactivation of GNG7 expression by 5-AZAC treatment
In 9 out of 15 (60%) oesophageal cell lines (TE3, TE4, TE5, TE8,
TE9, TE13, KYSE110, KYSE140 and KYSE170), GNG7 expression
was restored by 5-AZAC treatment (Figure 2B and C). Thus,
promoter hypermethylation may have contributed to GNG7
suppression.
Methylation analysis of the GNG7 promoter region in
clinical oesophageal cancer
Methylation of the GNG7 promoter region was assessed in 42
oesophageal cancer patients (paired tumour and normal DNA). To
evaluate DNA methylation patterns in the promoter region of the
GNG7 gene, we carried out bisulphite sequencing in five paired
cancer and normal tissue specimens. These five cases showed
suppressed GNG7 expression in tumour tissue compared with
normal tissue. There are 41 CG arrangements in the promoter
region of GNG7. Although most of these CG arrangements were
methylated in both tumour and normal DNA samples, there were
some unmethylated CG arrangements in normal DNA samples
compared with corresponding tumour DNA samples (data not
shown). On the basis of these findings, we utilised quantitative
methylation analysis (pyrosequencing analysis) (Figure 3B).
In pyrosequencing analysis, the frequencies of hypermethylated
CG arrangements in oesophageal cancer cases were 10 out of 42
(24%) and 6 out of 42 (14%) at regions 1 and 2, respectively.
Overall, hypermethylation was detected in 14 out of 42 (33%)
tumours in one of the two CG regions at the GNG7 promoter. We
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Figure 3 Genetic alterations of the GNG7-coding region. (A) Two representative oesophageal cancer cases that were positive (left) or negative (right) for
LOH. (B) Results of pyrosequencing analysis in a CG-rich region. Region #2 did not show any alterations by bisulphite treatment. However, region #1
showed that nucleotide C was increased in tumour tissues relative to corresponding normal tissue, and nucleotide T was decreased in tumour compared to
corresponding normal tissue. This trial focused on the CG site with cancer-specific CG arrangements. (C) Classification of 42 cases of oesophageal cancer
according to LOH status at GNG7 region and/or promoter hypermethylation. No genetic and/or epigenetic alterations were detected in eight cases (100%)
of oesophageal cancer that lacked suppression of GNG7 (T/No0.8) expression. In contrast, LOH and/or hypermethylation were found in 22 out of 34 cases
(65%) with diminished GNG7 expression.
Table 2 Relationship between the loss of GNG7 expression and the
genetic and/or epigenetic alteration in its loci
LOH Hypermethylation
  +N I   +
GNG7 expression
T/No0.8 24 10 0 20 14
0.8oT/N 6 0 2 8 0
P-value 0.0043 0.0065
GNG7¼G protein gamma 7; LOH¼loss of heterozygosity; T/N¼expression ratio
of GNG7 between tumour and the corresponding normal tissues.
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methylation and GNG7 expression status (Table 2). All 14
hypermethylation-positive cases (100%) had suppressed GNG7
expression (T/No0.8). There was a significant correlation between
the presence of hypermethylation and GNG7 expression status
(Po0.01). These data suggest that promoter hypermethylation
may contribute to the mechanism of GNG7 suppression.
Correlations among hypermethylation, LOH and RNA
expression
We analysed the correlation between GNG7 gene expression and
various mechanisms of gene suppression. That is, we determined if
there were correlations between the levels of mRNA expression
and promoter hypermethylation status and/or LOH at GNG7
region (Figure 3C). Interestingly, there was a significant correla-
tion between expression and the pattern of hypermethylation and
LOH at GNG7 (Po0.01). In the eight cases of normal GNG7
expression (0.8oT/N), there were no cases with either promoter
hypermethylation or LOH. In the 34 cases with GNG7 suppression
(T/Np0.8), there were two cases with both LOH and promoter
hypermethylation. There were eight patients positive for LOH and
12 that showed promoter hypermethylation. Thus, in 34 patients
showing GNG7 suppression (T/Np0.8), 22 cases (65%) could be
explained by LOH and/or promoter hypermethylation.
Significant association between expression of GNG7 and
microRNAs
In Figure 4, GNG7 expression was inversely and significantly
associated with miR328 expression (Po0.05) in 16 oesophageal
cancer cell lines. The expression of miR15a also tended to be
inversely associated with the level of GNG7 expression, but the
correlation did not reach significance. Therefore, these experi-
ments showed that GNG7 could be repressed by miR328.
DISCUSSION
In this study, we demonstrated that expression of GNG7 was
frequently (82% of cases) and strongly suppressed in oesophageal
cancer tissues compared with normal oesophageal tissues. We also
found that GNG7 suppression was associated with invasiveness
and poorer prognosis. The latter may be due to the former because
we found that re-expression of the GNG7 gene in oesophageal
cancer cell lines reduced invasiveness.
We analysed the mechanism by which GNG7 expression was
reduced in oesophageal cancer. Loss of chromosome 19p13.3,
which includes the GNG7 locus, has been observed frequently in
several cancers (Ritland et al, 1995; Hoglund et al, 1998; Wang
et al, 1999; Kato et al, 2004; Miyai et al, 2004; Yang et al, 2004).
Furthermore, STK11, the Peutz–Jeghers gene, is also located on
the telomeric region of chromosome 19p13.3 (Hemminki et al,
1998; Jenne et al, 1998). In our oesophageal cancer study, LOH in
GNG7 region (19p13.3) was detected in 10 out of 40 patients (25%).
In fact, LOH was significantly correlated with reduced GNG7
expression (Po0.01). Thus, GNG7 suppression was partially
related to LOH in oesophageal cancer. However, an epigenetic
alteration may also explain the reduced expression of GNG7 in
oesophageal cancer.
In oesophageal cancer, it is known that p16, FHIT and VHL are
inactivated by promoter hypermethylation (Wong et al, 1997;
Kuroki et al, 2003). We showed that expression of GNG7 in
oesophageal cancer cell lines could be restored by treatment with
the demethylating drug 5-AZAC. This suggests that in a model
system, GNG7 promoter hypermethylation might be responsible
for silencing GNG7 expression. Extending that observation, we also
found GNG7 promoter hypermethylation in oesophageal cancer
tissues. Taken together, these data suggest that promoter
hypermethylation may be intimately associated with GNG7
suppression.
Interestingly, this study demonstrated that GNG7 promoter
hypermethylation occurred in advanced stage tumours as well as
in early tumours. Specifically, it was recognised in 3 out of 12
tumours restricted within the oesophageal wall. These three
included one tumour of submucosal invasion and two tumours
of proper muscular invasion. Therefore, based on these findings,
we suggest that the hypermethylation of the GNG7 promoter might
be an early event in the progression of oesophageal cancer.
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Figure 4 Relationship between GNG7 expression and two predicted
microRNAs, miR15a and miR328. (A) miR15a tended to be associated
with GNG7 expression in 10 cell lines (TE6, TE8, TE10, TE12, KYSE110,
KYSE450, KYSE700, KSE1 and KSE2) (r¼0.617, P¼0.058). (B) There was
a significant association between miR328 and GNG7 expression in TE6,
TE8, TE10, TE12, TE15, KYSE110, KYSE140, KYSE180, KYSE220, KYSE270,
KYSE450, KYSE500, KYSE700, KSE1 and KSE2. (C) Expression of miR328
and miR15a was highly correlated (r¼0.96, Po0.001).
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of the promoter region of GNG7 revealed that it was moderately
methylated in non-cancerous oesophageal tissue (data not shown).
The presence of hypermethylation in corresponding non-
cancerous tissue may indicate a precancerous condition in the
surrounding non-cancerous area of the tumour. In fact, Eads et al
(2001) reported a similar phenomenon: moderate promoter
methylation in non-cancerous tissue and increased methylation
in cancer tissue.
Finally, we demonstrated that microRNAs may modulate GNG7
translation. The presence of the predicted microRNAs was
significantly associated with GNG7 expression. Thus, expression
of GNG7 may be partially controlled by microRNAs. At this point,
there are insufficient data to determine the extent to which
genomic alteration, hetero- and homo-allelic loss, epigenetic
alterations (as methylation) and microRNAs contribute to altered
GNG7 expression. Esquela-Kerscher and Slack (2006) reported that
microRNA is an abundant class of small, non-protein-coding
RNAs that function as negative gene regulators. Our data confirm
that finding. Chen (2005) reported that microRNA itself can be an
oncogene or a suppressor gene. The present study is the first to
demonstrate the role of miR328 in the regulation of a cancer
suppressor gene, GNG7. In accordance with the finding of cancer
cell lines that seven oesophageal cancer cell lines with more than
two times higher reactivation by DAC treatment were not
associated with the level of miR328 expression; we therefore
speculated that there should be no relationship between miR328
status and the epigenetic and genetic alterations in determining the
GNG7 mRNA expression in clinical oesophageal cancers. In
addition, we found that the presence of miR328 and miR15a was
closely associated with one another (Figure 4C, r¼0.96, Po0.001).
Therefore, a common upstream factor may control both miR328
and miR15a to regulate GNG7 expression.
In summary, we demonstrated that GNG7 was frequently and
strongly suppressed in oesophageal cancer. GNG7 suppression was
associated with greater invasiveness of cancer cells in the
oesophageal wall and poorer prognosis. Its expression was
suppressed by LOH at the GNG7 locus and epigenetic hyper-
methylation of the GNG7 promoter, and regulated by at least two
microRNAs. Further analysis of the signal cascade through which
GNG7 acts is needed to understand its precise molecular function.
We anticipate that analysis of GNG7 expression should provide an
important prognostic indicator in the near future.
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